Evidence map›Paper›PMID 36015134›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Search for Novel Potent Inhibitors of the SARS-CoV-2 Papain-like Enzyme: A Computational Biochemistry Approach.

Manuel I Osorio, Osvaldo Yáñez, Mauricio Gallardo, Matías Zuñiga-Bustos, Jorge Mulia-Rodríguez, Roberto López-Rendón, Olimpo García-Beltrán, Fernando González-Nilo, José M Pérez-Donoso

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Manuel I OsorioCenter for Bioinformatics and Integrative Biology (CBIB), Facultad de Ciencias de la Vida, Universidad Andres Bello, Av. República 330, Santiago 8370146, Chile.
Osvaldo YáñezCenter of New Drugs for Hypertension (CENDHY), Santiago 8380494, Chile.ORCID 0000-0001-8993-9353
Mauricio GallardoFacultad de Medicina, Centro de Investigación Biomédica, Universidad Diego Portales, Ejército 141, Santiago 8320000, Chile.
Matías Zuñiga-BustosCenter for Bioinformatics, Simulation and Modelling, Facultad de Ingeniería, Universidad de Talca, Talca 3465548, Chile.
Jorge Mulia-RodríguezLaboratorio de Bioingeniería Molecular a Multiescala, Facultad de Ciencias, Av. Instituto Literario 100, Universidad Autónoma del Estado de México, Toluca 50000, Mexico.
Roberto López-RendónLaboratorio de Bioingeniería Molecular a Multiescala, Facultad de Ciencias, Av. Instituto Literario 100, Universidad Autónoma del Estado de México, Toluca 50000, Mexico.
Olimpo García-BeltránFacultad de Ciencias Naturales y Matemáticas, Universidad de Ibagué, Carrera 22 Calle 67, Ibagué 730002, Colombia.ORCID 0000-0003-3312-1776
Fernando González-NiloCenter for Bioinformatics and Integrative Biology (CBIB), Facultad de Ciencias de la Vida, Universidad Andres Bello, Av. República 330, Santiago 8370146, Chile.
José M Pérez-DonosoCenter for Bioinformatics and Integrative Biology (CBIB), Facultad de Ciencias de la Vida, Universidad Andres Bello, Av. República 330, Santiago 8370146, Chile.ORCID 0000-0002-9506-1716
Universidad Andrés Bello · CLUniversidad Autónoma del Estado de México · MXCenter of New Drugs for Hypertension · CLUniversidad Bernardo O'Higgins · CLUniversidad Diego Portales · CLUniversity of Talca · CL

Funding

Fondecyt Postdoctoral 3201013
6 · The paper itself

Abstract

The rapid emergence and spread of new variants of coronavirus type 2, as well as the emergence of zoonotic viruses, highlights the need for methodologies that contribute to the search for new pharmacological treatments. In the present work, we searched for new SARS-CoV-2 papain-like protease inhibitors in the PubChem database, which has more than 100 million compounds. Based on the ligand efficacy index obtained by molecular docking, 500 compounds with higher affinity than another experimentally tested inhibitor were selected. Finally, the seven compounds with ADME parameters within the acceptable range for such a drug were selected. Next, molecular dynamics simulation studies at 200 ns, ΔG calculations using molecular mechanics with generalized Born and surface solvation, and quantum mechanical calculations were performed with the selected compounds. Using this in silico protocol, seven papain-like protease inhibitors are proposed: three compounds with similar free energy (D28, D04, and D59) and three compounds with higher binding free energy (D60, D99, and D06) than the experimentally tested inhibitor, plus one compound (D24) that could bind to the ubiquitin-binding region and reduce the effect on the host immune system. The proposed compounds could be used in in vitro assays, and the described protocol could be used for smart drug design.

Indexed as

binding free energymolecular dynamics simulationpapain-like protease of SARS-CoV-2virtual screening

Identifiers

PMID36015134
PMCPMC9414997
OpenAlexW4291017320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.